Thrombin generation test for evaluation of antiplatelet treatment in patients with coronary artery disease after percutaneous coronary intervention. (17th February 2018)

• Record Type: Journal Article
• Authors: Berezovskaya, Gelena; Smirnova, Olga; Malev, Eduard; Khromov-Borisov, Nikita; Klokova, Elena; Karpenko, Mikhail; Papayan, Lyudmila; Petrishchev, Nikolay
• Is Part Of: Platelets. Volume 29:Number 2(2018)
• Page Start: 185
• Page End: 191
• Publication Date: 2018-02-17
• Subjects: Antiplatelet drugs -- coronary artery disease -- percutaneous coronary intervention -- thrombin generation test; Blood platelets -- Periodicals; Blood Platelets -- Periodicals; 615.39
• DOI: 10.1080/09537104.2017.1294680
• Languages: English
• ISSNs: 0953-7104

Abstract

Abstract: To study the possibility of using thrombin generation tests in platelet-rich and platelet-poor plasma for evaluation of dual antiplatelet therapy efficacy in patients with coronary artery disease (CAD), following percutaneous coronary intervention. Venous blood was analyzed from CAD patients aged 53–75 years who had undergone percutaneous coronary intervention with stenting within one year and had been receiving standard doses of clopidogrel and aspirin (75 and 75–100 mg per day, respectively). The control group comprised age- and sex-matched subjects without clinical signs of CAD who were not receiving these drugs. Thrombin generation tests were performed in platelet-rich and platelet-poor plasma. Intravascular platelet activation, induced platelet aggregation, and routine coagulation were evaluated. Antiplatelet treatment did not influence results of routine coagulation tests or intravascular platelet activation. The dual antiplatelet therapy affects collagen-induced platelet aggregation (44 ± 2.5 vs. 7.9 ± 2.6%, р = 10 −7 ) and leads to decreases in endogenous thrombin potential (1900 ± 85 vs. 1740 ± 95 nM∙min, p = 0.0045), maximum thrombin concentration (134 ± 9.5 vs. 106 ± 6.5 nM, p = 4∙10 −6 ), and increases in time to peak thrombin (27 ± 1.5 vs. 31 ± 2 min, p = 0.0012). Decreases in thrombin generation rate showed the highest statistical significance (13 ± 2 vs. 7.9 ± 0.8 nM/min, p = 10 −8 ). Antiplatelet treatment did not alter thrombogram parameters for platelet-poor plasma.